We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Automated Nucleic Acid Extraction/Superfast PCR Platform to Enable Analysis of POC PCR Tests in Minutes

By LabMedica International staff writers
Posted on 28 Apr 2022
Print article
Image: The XDive superfast qPCR platform (Photo courtesy of Star Array)
Image: The XDive superfast qPCR platform (Photo courtesy of Star Array)

Over the past three decades, the real-time PCR technology has revolutionized the biological science with its sensitive and reliable performances, easy-to-use and to-automate workflow, and vast range of applications. Now, this legend could become even better, i.e. faster. An automated nucleic acid extraction/superfast PCR platform for the Point-of-Care testing (POCT) market could enable POC PCR tests to be analyzed in just minutes in doctor's offices, laboratories, and hospitals.

Zymo Research (Irvine, CA, USA) has made a strategic investment to acquire an interest in Star Array (Singapore) that would allow them to combine Zymo’s nucleic acid purification and assay technologies with Star Array's engineering and automation expertise to expand into emerging For Research Use Only (FRUO) and diagnostic markets, including POCT.

Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology. It manufactures and markets various genetic analyzers including XDive, a superfast qPCR platform, with related kits and software. During the COVID-19 outbreak, Star Array developed a test for SARS-CoV-2 detection utilizing its XDive system. The entire process from sample-to-answer takes less than 45 minutes and the system can be used in any clinical environment. Star Array is currently working through the Emergency Use Authorization (EUA) process with the U.S. Food and Drug Administration (FDA). Zymo, which is well known for its DNA/RNA extraction and assay technologies, will be partnering with Star Array to develop ready-made cassettes containing the necessary reagents for Star Array's COVID-19 test kit as well as future POCT.

"Star Array's powerful PCR instrumentation places them at the forefront of PCR technology with their XDive PCR system that can complete a typical 40-cycle multiplex qPCR run in 5-7 minutes. When coupled with Star Array's system, Zymo Research's DNA/RNA purification reagents and nucleic acid-based assays will facilitate a straightforward Sample-In/Answer-Out workflow. Through our investment in Star Array we will develop products targeting POCT in the global marketplace," said Marc Van Eden, Vice President of Business Development at Zymo Research.

"Zymo Research and Star Array have both built businesses at the intersection of science and technology and we share a vision of ultrafast PCR technology that will enable POC PCR tests to be analyzed in just minutes in doctor's offices, laboratories, and hospitals. Together we strive to build even more POCT products in the future," said Dr. Yanhui Liu, Vice President of Star Array Pte. Ltd.

Related Links:
Zymo Research 
Star Array 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.